Interference with RhoAROCK signaling mechanism in autoreactive CD4 + T cells enhances the bioavailability of 1,25-dihydroxyvitamin D 3 in experimental autoimmune encephalomyelitis

American Journal of Pathology

Volumn 181, Issue 3, 2012, Pages 993-1006

  Paintlia, Ajaib S ^a   Paintlia, Manjeet K ^a   Hollis, Bruce W ^a   Singh, Avtar K ^b   Singh, Inderjit ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; CALCIFEDIOL; CALCITRIOL; FASUDIL; GGTI 298; MEVALONOLACTONE; MEVINOLIN; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; MEVALONIC ACID; PROTEIN KINASE INHIBITOR; RHO KINASE; STEROID MONOOXYGENASE; VITAMIN D; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; KIDNEY; LYMPHOID ORGAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; VITAMIN METABOLISM; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GUINEA PIG; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEWIS RAT; LYMPHOID TISSUE; METABOLISM; MICROBIOLOGY; PATHOLOGY; SPINAL CORD;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; BIOLOGICAL AVAILABILITY; BIOSYNTHETIC PATHWAYS; CALCITRIOL; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GUINEA PIGS; IMMUNOSUPPRESSION; INFLAMMATION; LOVASTATIN; LYMPHOID TISSUE; MEVALONIC ACID; PROTEIN KINASE INHIBITORS; RATS; RATS, INBRED LEW; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SPINAL CORD; STEROID HYDROXYLASES; VITAMIN D;

EID: 84865227307     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.05.028     Document Type: Article

References (65)

1. J. Al-Omaishi, R. Bashir, H.E. Gendelman The cellular immunology of multiple sclerosis J Leukoc Biol 65 1999 444 452
2. J.W. Prineas, R.O. Barnard, E.E. Kwon, L.R. Sharer, E.S. Cho Multiple sclerosis: remyelination of nascent lesions Ann Neurol 33 1993 137 151
3. E. Bettelli, Y. Carrier, W. Gao, T. Korn, T.B. Strom, M. Oukka, H.L. Weiner, V.K. Kuchroo Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
4. J. Zhu, W.E. Paul Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors Immunol Rev 238 2010 247 262
5. R.A. Marrie Environmental risk factors in multiple sclerosis aetiology Lancet Neurol 3 2004 709 718
6. B.D. Beretich, T.M. Beretich Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis Mult Scler 15 2009 891 898
7. C.E. Hayes Vitamin D: a natural inhibitor of multiple sclerosis Proc Nutr Soc 59 2000 531 535
8. J.L. Omdahl, H.A. Morris, B.K. May Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation Annu Rev Nutr 22 2002 139 166
9. S.V. Ramagopalan, D.A. Dyment, M.Z. Cader, K.M. Morrison, G. Disanto, J.M. Morahan, A.J. Berlanga-Taylor, A. Handel, G.C. De Luca, A.D. Sadovnick, P. Lepage, A. Montpetit, G.C. Ebers Rare variants in the CYP27B1 gene are associated with multiple sclerosis Ann Neurol 70 2011 881 886
10. M.R. Haussler, G.K. Whitfield, C.A. Haussler, J.C. Hsieh, P.D. Thompson, S.H. Selznick, C.E. Dominguez, P.W. Jurutka The nuclear vitamin D receptor: biological and molecular regulatory properties revealed J Bone Miner Res 13 1998 325 349
11. T. Fukazawa, I. Yabe, S. Kikuchi, H. Sasaki, T. Hamada, K. Miyasaka, K. Tashiro Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese J Neurol Sci 166 1999 47 52
12. M. Niino, T. Fukazawa, I. Yabe, S. Kikuchi, H. Sasaki, K. Tashiro Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles J Neurol Sci 177 2000 65 71
13. M.T. Cantorna, C.E. Hayes, H.F. DeLuca 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis Proc Natl Acad Sci USA 93 1996 7861 7864
14. K.M. Spach, L.B. Pedersen, F.E. Nashold, T. Kayo, B.S. Yandell, T.A. Prolla, C.E. Hayes Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis Physiol Genomics 18 2004 141 151
15. S. Joshi, L.C. Pantalena, X.K. Liu, S.L. Gaffen, H. Liu, C. Rohowsky-Kochan, K. Ichiyama, A. Yoshimura, L. Steinman, S. Christakos, S. Youssef 1,25-Dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A Mol Cell Biol 31 2011 3653 3669
16. K.M. Spach, C.E. Hayes Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice J Immunol 175 2005 4119 4126
17. C.G. Mayne, J.A. Spanier, L.M. Relland, C.B. Williams, C.E. Hayes 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis Eur J Immunol 41 2011 822 832
18. K.L. Munger, L.I. Levin, B.W. Hollis, N.S. Howard, A. Ascherio Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis JAMA 296 2006 2832 2838
19. K.L. Munger, S.M. Zhang, E. O'Reilly, M.A. Hernan, M.J. Olek, W.C. Willett, A. Ascherio Vitamin D intake and incidence of multiple sclerosis Neurology 62 2004 60 65
20. J.M. Burton, S. Kimball, R. Vieth, A. Bar-Or, H.M. Dosch, R. Cheung, D. Gagne, C. D'Souza, M. Ursell, P. O'Connor A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis Neurology 74 2010 1852 1859
21. M.S. Stein, Y. Liu, O.M. Gray, J.E. Baker, S.C. Kolbe, M.R. Ditchfield, G.F. Egan, P.J. Mitchell, L.C. Harrison, H. Butzkueven, T.J. Kilpatrick A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis Neurology 77 2011 1611 1618
22. S.M. Kimball, M.R. Ursell, P. O'Connor, R. Vieth Safety of vitamin D3 in adults with multiple sclerosis Am J Clin Nutr 86 2007 645 651
23. J. Smolders, R. Hupperts, F. Barkhof, L.M. Grimaldi, T. Holmoy, J. Killestein, P. Rieckmann, M. Schluep, R. Vieth, U. Hostalek, L. Ghazi-Visser, M. Beelke Efficacy of vitamin D(3) as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a phase II, multicenter, double-blind, randomized, placebo-controlled trial J Neurol Sci 311 2011 44 49
24. F. Kamezaki, S. Sonoda, Y. Tomotsune, H. Yunaka, Y. Otsuji Seasonal variation in serum lipid levels in Japanese workers J Atheroscler Thromb 17 2010 638 643
25. P.R. Woodhouse, K.T. Khaw, M. Plummer Seasonal variation of serum lipids in an elderly population Age Ageing 22 1993 273 278
26. J.L. Perez-Castrillon, G. Vega, L. Abad, A. Sanz, J. Chaves, G. Hernandez, A. Duenas Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease Am J Cardiol 99 2007 903 905
27. D.T. Ertugrul, B. Yavuz, H. Cil, N. Ata, K.O. Akin, M. Kucukazman, A.A. Yalcin, K. Dal, B.B. Yavuz, E. Tutal STATIN-D Study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxyvitamin D Cardiovasc Ther 2 2010 146 152
28. T. Vollmer, L. Key, V. Durkalski, W. Tyor, J. Corboy, S. Markovic-Plese, J. Preiningerova, M. Rizzo, I. Singh Oral simvastatin treatment in relapsing-remitting multiple sclerosis Lancet 363 2004 1607 1608
29. R. Lanzillo, G. Orefice, M. Quarantelli, C. Rinaldi, A. Prinster, G. Ventrella, D. Spitaleri, G. Lus, G. Vacca, B. Carotenuto, E. Salvatore, A. Brunetti, G. Tedeschi, V. Brescia Morra Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy Mult Scler 16 2010 450 454
30. X. Zhang, J. Jin, X. Peng, V.S. Ramgolam, S. Markovic-Plese Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes J Immunol 180 2008 6988 6996
31. A.S. Paintlia, M.K. Paintlia, A.K. Singh, I. Singh Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis Mol Pharmacol 73 2008 1381 1393
32. S.E. Dunn, S. Youssef, M.J. Goldstein, T. Prod'homme, M.S. Weber, S.S. Zamvil, L. Steinman Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J Exp Med 203 2006 401 412
33. C.D. Nobes, A. Hall Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia Cell 81 1995 53 62
34. A.S. Paintlia, M.K. Paintlia, M. Khan, T. Vollmer, A.K. Singh, I. Singh HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis FASEB J 19 2005 1407 1421
35. A.S. Paintlia, M.K. Paintlia, A.K. Singh, R. Stanislaus, A.G. Gilg, E. Barbosa, I. Singh Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by lovastatin J Neurosci Res 77 2004 63 81
36. B.W. Hollis Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers Methods Enzymol 282 1997 174 186
37. D.M. Kerry, P.P. Dwivedi, C.N. Hahn, H.A. Morris, J.L. Omdahl, B.K. May Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter J Biol Chem 271 1996 29715 29721
38. M.T. Cantorna, C.E. Hayes, H.F. DeLuca 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis J Nutr 128 1998 68 72
39. J. Correale, M.C. Ysrraelit, M.I. Gaitan Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects J Immunol 185 2010 4948 4958
40. C.G. Mayne, J.A. Spanier, L.M. Relland, C.B. Williams, C.E. Hayes 1,25-Dihydroxyvitamin D3 acts directly on the T lymphocyte vitamin D receptor to inhibit experimental autoimmune encephalomyelitis Eur J Immunol 41 2011 822 832
41. D.J. Bettoun, T.P. Burris, K.A. Houck, D.W. Buck 2nd, K.R. Stayrook, B. Khalifa, J. Lu, W.W. Chin, S. Nagpal Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation Mol Endocrinol 17 2003 2320 2328
42. K. Prufer, A. Racz, G.C. Lin, J. Barsony Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors J Biol Chem 275 2000 41114 41123
43. L. Szeles, S. Poliska, G. Nagy, I. Szatmari, A. Szanto, A. Pap, M. Lindstedt, S.J. Santegoets, R. Ruhl, B. Dezso, L. Nagy Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells Mol Endocrinol 24 2010 2218 2231
44. Y. Shen, H. Wu, C. Wang, H. Shao, H. Huang, H. Jing, D. Li Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor gamma Eur J Pharmacol 649 2010 255 262
45. A.S. Paintlia, M.K. Paintlia, A.K. Singh, J.K. Orak, I. Singh Activation of PPAR-gamma and PTEN cascade participates in lovastatin-mediated accelerated differentiation of oligodendrocyte progenitor cells Glia 58 2010 1669 1685
46. N. Nath, S. Giri, R. Prasad, A.K. Singh, I. Singh Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy J Immunol 172 2004 1273 1286
47. R.E. Botti, J. Triscari, H.Y. Pan, J. Zayat Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects Clin Neuropharmacol 14 1991 256 261
48. A.V. Kalueff, A. Minasyan, T. Keisala, M. Kuuslahti, S. Miettinen, P. Tuohimaa The vitamin D neuroendocrine system as a target for novel neurotropic drugs CNS Neurol Disord Drug Targets 5 2006 363 371
49. D.W. Eyles, S. Smith, R. Kinobe, M. Hewison, J.J. McGrath Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain J Chem Neuroanat 29 2005 21 30
50. D. Baas, K. Prufer, M.E. Ittel, S. Kuchler-Bopp, G. Labourdette, L.L. Sarlieve, P. Brachet Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25dihydroxyvitamin D(3) Glia 31 2000 59 68
51. S. Kawashima, T. Yamashita, Y. Miwa, M. Ozaki, M. Namiki, T. Hirase, N. Inoue, K. Hirata, M. Yokoyama HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats Stroke 34 2003 157 163
52. X. Bi, M. Baudry, J. Liu, Y. Yao, L. Fu, F. Brucher, G. Lynch Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia J Biol Chem 279 2004 48238 48245
53. A. Cordle, G. Landreth 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses J Neurosci 25 2005 299 307
54. D. Iglesias-Gato, S. Zheng, J.N. Flanagan, L. Jiang, A. Kittaka, T. Sakaki, K. Yamamoto, T. Itoh, N.K. Lebrasseur, G. Norstedt, T.C. Chen Substitution at carbon 2 of 19-nor-1alpha,25-dihydroxyvitamin D(3) with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells J Steroid Biochem Mol Biol 127 2011 269 275
55. J.R. Muindi, W.D. Yu, Y. Ma, K.L. Engler, R.X. Kong, D.L. Trump, C.S. Johnson CYP24A1 inhibition enhances the antitumor activity of calcitriol Endocrinology 151 2010 4301 4312
56. G. Birnbaum, B. Cree, I. Altafullah, M. Zinser, A.T. Reder Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis Neurology 71 2008 1390 1395
57. F. Paul, S. Waiczies, J. Wuerfel, J. Bellmann-Strobl, J. Dorr, H. Waiczies, M. Haertle, K.D. Wernecke, H.D. Volk, O. Aktas, F. Zipp Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis PLoS One 3 2008 e1928
58. P.S. Sorensen, J. Lycke, J.P. Eralinna, A. Edland, X. Wu, J.L. Frederiksen, A. Oturai, C. Malmestrom, E. Stenager, F. Sellebjerg, H.B. Sondergaard Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial Lancet Neurol 10 2011 691 701
59. R.A. Rudick, A. Pace, M.R. Rani, R. Hyde, M. Panzara, S. Appachi, J. Shrock, S.L. Maurer, P.A. Calabresi, C. Confavreux, S.L. Galetta, F.D. Lublin, E.W. Radue, R.M. Ransohoff Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a Neurology 72 2009 1989 1993
60. C.P. Kamm, M. El-Koussy, S. Humpert, O. Findling, F. von Bredow, Y. Burren, G. Schwegler, D. Schott, F. Donati, M. Muller, N. Goebels, F. Muller, J. Slotboom, B. Tettenborn, L. Kappos, Y. Naegelin, H.P. Mattle Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial J Neurol 2012 10.1007/s00415-012-6513-7
61. S.S. Zamvil, L. Steinman Combining statins with interferon beta in multiple sclerosis: think twice, it might not be all right Lancet Neurol 10 2011 672 673
62. O. Stuve, S. Youssef, M.S. Weber, S. Nessler, H.C. von Budingen, B. Hemmer, T. Prod'homme, R.A. Sobel, L. Steinman, S.S. Zamvil Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity J Clin Invest 116 2006 1037 1044
63. A.S. Paintlia, M.K. Paintlia, I. Singh, A.K. Singh Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis Exp Neurol 214 2008 168 180
64. A.S. Paintlia, M.K. Paintlia, I. Singh, A.K. Singh Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis Am J Pathology 169 2006 1012 1025
65. I. Luccarini, C. Ballerini, T. Biagioli, F. Biamonte, A. Bellucci, M.C. Rosi, C. Grossi, L. Massacesi, F. Casamenti Combined treatment with atorvastatin and minocycline suppresses severity of EAE Exp Neurol 211 2008 214 226